Antioxidant therapy and neuroprotection in the newborn

Pediatric Health

Volumn 2, Issue 6, 2008, Pages 715-732

  Perrone, Serafina ^a   Turrissi, Giovanni ^a   Buonocore, Giuseppe ^b  

^a University of Siena ^*  (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Antioxidants; Brain injury; Free radicals; Neuroprotection; Newborn infant; Oxidative stress

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALBUMIN; ALLOPURINOL; ALPHA TOCOPHEROL; ANTIOXIDANT; APOPTOSIS INDUCING FACTOR; BETA CAROTENE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IV; CASPASE 3; CASPASE 9; DEFEROXAMINE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FREE RADICAL; GLUTAMIC ACID; GLUTAMINE; I KAPPA B; IRON; ISOPROSTANE DERIVATIVE; MAGNESIUM SULFATE; MELATONIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NONPROTEIN BINDING IRON; OXYGEN; PLACEBO; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTIFICIAL VENTILATION; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN INJURY; BRAIN ISCHEMIA; CLINICAL TRIAL; COOLING; DNA DAMAGE; DRUG MEGADOSE; HOMEOSTASIS; HUMAN; HYPOTHERMIA; HYPOXIA; INFLAMMATION; LEUKOMALACIA; LIPID PEROXIDATION; LOW DRUG DOSE; MICROGLIA; NEUROPROTECTION; NEWBORN CARE; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PATHOGENESIS; PERFUSION PRESSURE; PERIVENTRICULAR LEUKOMALACIA; REPERFUSION INJURY; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; STROKE;

EID: 70349647323     PISSN: 17455111     EISSN: None     Source Type: Journal    
DOI: 10.2217/17455111.2.6.715     Document Type: Review

References (173)

1. Vincer MJ, Allen AC, Joseph KS, Stinson DA, Scott H, Wood E: Increasing prevalence of cerebral palsy among very preterm infants: a population-based study. Pediatrics 118(6), E1621-E1626 (2006).
2. Pierrat V, Haouari N, Liska A, Thomas D, Subtil D, Truffert P: Groupe d'Etudes en Epidémiologie Périnatale. Prevalence, causes, and outcome at 2 years of age of newborn encephalopathy: population based study. Arch. Dis. Child. Fetal Neonatal Ed. 90(3), F257-F261 (2005).
3. Foley ME, Alarab M, Daly L, Keane D, Macquillan K, O'Herlihy C: Term neonatal asphyxial seizures and peripartum deaths: lack of correlation with a rising cesarean delivery rate. Am. J. Obstet. Gynecol. 192(1), 102-108 (2005).
4. Pleacher MD, Vohr BR, Katz KH, Ment LR, Allan WC: An evidence-based approach to predicting low IQ in very preterm infants from the neurological examination: outcome data from the indomethacin Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics 113(2), 416-419 (2004).
5. Hagberg H: Mitochondrial impairment in the developing brain after hypoxia-ischemia. J. Bioenerg. Biomembr. 36(4), 369-373 (2004).
6. Rees S, Inder T: Fetal and neonatal origins of altered brain development. Early Hum. Dev. 81(9), 753-761 (2005).
7. Volpe JJ: Hypoxic-ischemic encephalopathy. In: Neuropathology and Pathogenesis in Neurology of the Newborn. Volpe JJ (Ed.). Saunders, Elsevier, Philadelphia, PA, USA, 347-399 (2008).
8. Kerk J, Dördelmann M, Bartels DB et al.: Multiplex measurement of cytokine/receptor gene polymorphisms and interaction between interleukin-10 (-1082) genotype and chorioamnionitis in extreme preterm delivery. J. Soc. Gynecol. Investig. 13(5), 350-356 (2006).
9. Curry CJ, Bhullar S, Holmes J, Delozier CD, Roeder ER, Hutchison HT: Risk factors for perinatal arterial stroke: a study of 60 mother-child pairs. Pediatr. Neurol. (2), 99-107 (2007).
10. Reid S, Halliday J, Ditchfield M et al.: Factor V Leiden mutation: a contributory factor for cerebral palsy? Dev. Med. Child Neurol. 48(1), 14-19 (2006).
11. Bracci R, Buonocore G, Perrone S: The timing of neonatal brain damage. Biol. Neonate 90(3), 145-155 (2006).
12. Badawi N, Kurinczuk JJ, Keogh JM et al.: Intrapartum risk factors for newborn encephalopathy: the Western Australian case-control study. Br. Med. J. 317(7172), 1554-1558 (1998).
13. Mallard C, Hagberg H: Inflammation-induced preconditioning in the immature brain. Semin. Fetal Neonatal Med. 12(4), 280-286 (2007).
14. Favrais G, Couvineau A, Laburthe M, Gressens P, Lelievre V: Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge. Peptides 28(9), 1727-1737 (2007).
15. Chappell LC, Seed PT, Kelly FJ et al.: Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices of oxidative stress and placental function. Am. J. Obstet. Gynecol. 187(3), 777-784 (2002).
16. Saugstad OD: Mechanisms of tissue injury by oxygen radicals: implications for neonatal disease. Acta Paediatr. 85(1), 1-4 (1996).
17. 2-·), superoxide dismutases, and related matters. J. Biol. Chem. 272(30), 18515-18517 (1997).
18. Dröge W: Free radicals in the physiological control of cell function. Physiol. Rev. 82(1), 47-95 (2002).
19. Buonocore G, Groenendaal F: Anti-oxidant strategies. Semin. Fetal Neonatal Med. 12(4), 287-295 (2007).
20. Ferriero DM: Oxidant mechanisms in neonatal hypoxia-ischemia. Dev. Neurosci. 23(3), 198-202 (2001).
21. Schaller B: Prospects for the future: the role of free radicals in the treatment of stroke. Free Radic. Biol. Med. 38(4), 411-425 (2005).
22. Folkerth RD, Haynes RL, Borenstein NS et al.: Developmental lag in superoxide dismutases relative to other antioxidant enzymes in premyelinated human telencephalic white matter. J. Neuropathol. Exp. Neurol. 63(9), 990-999. (2004).
23. Khan JY, Black SM: Developmental changes in murine brain antioxidant enzymes. Pediatr. Res. 54(1), 77-82 (2003).
24. McQuillen PS, Ferriero DM: Selective vulnerability in the developing central nervous system. Pediatr. Neurol. 30(4), 227-235 (2004).
25. Iida K, Takashima S, Ueda K: Immunohistochemical study of myelination and oligodendrocyte in infants with periventricular leukomalacia. Pediatr. Neurol. 13(4), 296-304 (1995).
26. Connor JR, Menzies SL: Relationship of iron to oligodendrocytes and myelination. Glia 17(2), 83-93 (1996).
27. Perrone S, Bracci R, Buonocore G: New biomarkers of fetal-neonatal hypoxic stress. Acta Paediatr. Suppl. 91(438), 135-138 (2002).
28. Bracci R, Buonocore G. Chorioamnionitis: a risk factor for fetal and neonatal morbidity. Biol. Neonate 83(2), 85-96 (2003).
29. Fiskum G, Rosenthal RE, Vereczki V et al.: Protection against ischemic brain injury by inhibition of mitochondrial oxidative stress. J. Bioenerg. Biomembr. 36(4), 347-352. (2004).
30. 2+-influx. Neurochem. Res. 33(7), 1196-1204 (2008).
31. Mishra OP, Zubrow AB, Ashraf QM, Delivoria-Papadopoulos M: Effect of nitric oxide synthase inhibition during post-hypoxic reoxygenation on Bax and Bcl-2 protein expression and DNA fragmentation in neuronal nuclei of newborn piglets. Brain Res. 1101(1), 20-28 (2006)
32. Arundine M, Tymianski M: Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 34(4-5), 325-337 (2003)
33. Johnston MV: Excitotoxicity in perinatal brain injury. Brain Pathol. 15(3), 234-240 (2005).
34. Brazel CY, Nuñez JL, Yang Z, Levison SW: Glutamate enhances survival and proliferation of neural progenitors derived from the subventricular zone. Neuroscience 131(1), 55-65 (2005)
35. 2+ from intracellular stores and is prevented by estradiol. Eur. J. Neurosci. 24(11), 3008-3016 (2006)
36. Babu GN, Bawari M, Ali MM: Lipid peroxidation potential and antioxidant status of circumventricular organs of rat brain following neonatal monosodium glutamate. Neurotoxicology 15(3), 773-777 (1994).
37. Sorrentino DF, Fritz KI, Haider SH, Parikh N, Papadopoulos MD, Mishra OP: Nitric oxide-mediated modification of the glycine binding site of the NMDA receptor during hypoxia in the cerebral cortex of the newborn piglet. Neurochem. Res. 29(2), 455-459 (2004)
38. Carden DL, Granger DN: Pathophysiology of ischaemia-reperfusion injury. J. Pathol. 190(3), 255-266 (2000).
39. Guix FX, Uribesalgo I, Coma M, Muñoz FJ: The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 76(2), 126-152 (2005).
40. Lipton SA, Choi YB, Pan ZH et al.: A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364(6438), 626-632 (1993).
41. Mishra OP, Mishra R, Ashraf QM, Delivoria-Papadopoulos M: Nitric oxide-mediated mechanism of neuronal nitric oxide synthase and inducible nitric oxide synthase expression during hypoxia in the cerebral cortex of newborn piglets. Neuroscience 140(3), 857-863 (2006)
42. Felderhoff-Mueser U, Bittigau P, Sifringer M et al.: Oxygen causes cell death in the developing brain. Neurobiol. Dis. 17(2), 273-282 (2004)
43. Mishra OP, Randis T, Ashraf QM, Delivoria-Papadopoulos M: Hypoxia-induced Bax and Bcl-2 protein expression, caspase-9 activation, DNA fragmentation, and lipid peroxidation in mitochondria of the cerebral cortex of newborn piglets: the role of nitric oxide. Neuroscience 141(3), 1339-1349 (2006).
44. Mehmet H, Yue X, Squier MV et al.: Increased apoptosis in the cingulate sulcus of newborn piglets following transient hypoxia-ischaemia is related to the degree of high energy phosphate depletion during the insult. Neurosi. Lett. 181(1-2), 121-125 (1994)
45. Green DR, Reed JC: Mitochondria and apoptosis. Science 281(5381), 1309-1312 (1998)
46. Zhivotovsky B, Orrenius S, Brustugun OT, Døskeland SO: Injected cytochrome c induces apoptosis. Nature 391(6666), 449-450 (1998)
47. 2+ mobilization by hypoxia-induced NO generation in rat brain striatal slices and human astrocytoma U-373 MG cells and its involvement in tissue damage. Eur. J. Neurosci. 17(4), 692-700 (2003)
48. Stewart VC, Heales SJ: Nitric oxide-induced mitochondrial dysfunction: implications for neurodegeneration. Free Radic. Biol. Med. 34(3), 287-303 (2003)
49. 2+-influx in neuronal nuclei and cortical synaptosomes of normoxic and hypoxic newborn piglets. Neurosci. Lett. 318(2), 93-97. (2002)
50. Berridge MJ, Bootman MD, Lipp P: Calcium - a life and death signal. Nature 395(6703), 645-648 (1998)
51. Ota K, Yakovlev AG, Itaya A, Kameoka M, Tanaka Y, Yoshihara K: Alteration of apoptotic protease-activating factor-1 (APAF-1)-dependent apoptotic pathway during development of rat brain and liver. J. Biochem. 131(1), 131-135 (2002)
52. Genestra M: Oxyl radicals, redox-sensitive signalling cascades and antioxidants. Cell. Signal. 19(9),1807-1819 (2007)
53. Baud O, Li J, Zhang Y, Neve RL, Volpe JJ, Rosenberg PA: Nitric oxide-induced cell death in developing oligodendrocytes is associated with mitochondrial dysfunction and apoptosis-inducing factor translocation. Eur. J. Neurosci. 20(7), 1713-1726 (2004)
54. Mronga T, Stahnke T, Goldbaum O, Richter-Landsberg C: Mitochondrial pathway is involved in hydrogen-peroxide-induced apoptotic cell death of oligodendrocytes. Glia 46(4), 446-455 (2004)
55. Gerstner B, DeSilva TM, Genz K et al.: Hyperoxia causes maturation-dependent cell death in the developing white matter. J. Neurosci. 28(5), 1236-1245 (2008)
56. De Felice C, Toti P, Laurini RN et al.: Early neonatal brain injury in histologic chorioamnionitis. J. Pediatr. 138(1), 101-104 (2001).
57. Mittendorf R, Montag AG, MacMillan W et al.: Components of the systemic fetal inflammatory response syndrome as predictors of impaired neurologic outcomes in children. Am. J. Obstet. Gynecol. 188(6), 1438-1444 (2003).
58. Yoon BH, Jun JK, Romero R et al.: Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1β, and tumor necrosis factor-α), neonatal brain white matter lesions, and cerebral palsy. Am. J. Obstet. Gynecol. 177(1), 19-26 (1997).
59. Minagawa K, Tsuji Y, Ueda H et al.: Possible correlation between high levels of IL-18 in the cord blood of pre-term infants and neonatal development of periventricular leukomalacia and cerebral palsy. Cytokine 17(3), 164-170 (2002).
60. Duggan PJ, Maalouf EF, Watts TL et al.: Intrauterine T-cell activation and increased proinflammatory cytokine concentrations in preterm infants with cerebral lesions. Lancet 358(9294), 1699-1700 (2001).
61. Nelson KB, Grether JK, Dambrosia JM et al.: Neonatal cytokines and cerebral palsy in very preterm infants. Pediatr. Res. 53(4), 600-607 (2003).
62. Kaukola T, Satyaraj E, Patel DD et al.: Cerebral palsy is characterized by protein mediators in cord serum. Ann. Neurol. 55(2), 186-194 (2004).
63. Locatelli A, Vergani P, Ghidini A et al.: Duration of labor and risk of cerebral white-matter damage in very preterm infants who are delivered with intrauterine infection. Am. J. Obstet. Gynecol. 193(3 Pt 2), 928-932 (2005).
64. Folkerth RD, Keefe RJ, Haynes RL, Trachtenberg FL, Volpe JJ, Kinney HC: Interferon-γ expression in periventricular leukomalacia in the human brain. Brain Pathol. 14(3), 265-274 (2004).
65. Kadhim H, Tabarki B, Verellen G, De Prez C, Rona AM, Sébire G: Inflammatory cytokines in the pathogenesis of periventricular leukomalacia. Neurology 56(10), 1278-1284 (2001).
66. Wang X, Hagberg H, Nie C, Zhu C, Ikeda T, Mallard C: Dual role of intrauterine immune challenge on neonatal and adult brain vulnerability to hypoxia-ischemia. J. Neuropathol. Exp. Neurol. 66(6), 552-561 (2007).
67. Wang X, Hagberg H, Zhu C, Jacobsson B, Mallard C: Effects of intrauterine inflammation on the developing mouse brain. Brain Res. 1144, 180-185 (2007).
68. Rousset CI, Chalon S, Cantagrel S et al.: Maternal exposure to LPS induces hypomyelination in the internal capsule and programmed cell death in the deep gray matter in newborn rats. Pediatr. Res. 59(3), 428-433 (2006).
69. Garnier Y, Coumans AB, Jensen A, Hasaart TH, Berger R: Infection-related perinatal brain injury: the pathogenic role of impaired fetal cardiovascular control. J. Soc. Gynecol. Investig. 10(8), 450-459 (2003).
70. Møller K, Strauss GI, Qvist J et al.: Cerebral blood flow and oxidative metabolism during human endotoxemia. J. Cereb. Blood Flow Metab. 22(10), 1262-1270 (2002).
71. Chakravarty S, Herkenham M: Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J. Neurosci. 25(7), 1788-1796 (2005).
72. Hagberg H, Mallard C: Effect of inflammation on central nervous system development and vulnerability. Curr. Opin. Neurol. 18(2), 117-123 (2005).
73. Pachter JS, de Vries HE, Fabry Z: The blood-brain barrier and its role in immune privilege in the central nervous system. J. Neuropathol. Exp. Neurol. 62(6), 593-604 (2003).
74. Eklind S, Hagberg H, Wang X et al.: Effect of lipopolysaccharide on global gene expression in the immature rat brain. Pediatr. Res. 60(2), 161-168 (2006).
75. Bell MJ, Hallenbeck JM, Gallo V: Determining the fetal inflammatory response in an experimental model of intrauterine inflammation in rats. Pediatr. Res. 56(4), 541-546 (2004).
76. Barger SW, Goodwin ME, Porter MM, Beggs ML: Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J. Neurochem. 101(5), 1205-1213 (2007).
77. Block ML, Hong JS: Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76(2), 77-98 (2005).
78. Didion SP, Kinzenbaw DA, Fegan PE, Didion LA, Faraci FM: Overexpression of CuZn-SOD prevents lipopolysaccharide-induced endothelial dysfunction. Stroke 35(8), 1963-1967 (2004).
79. Li J, Baud O, Vartanian T, Volpe JJ, Rosenberg PA: Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc. Natl Acad. Sci. USA 102(28), 9936-9941 (2005).
80. Baud O, Li J, Zhang Y, Neve RL, Volpe JJ, Rosenberg PA: Nitric oxide-induced cell death in developing oligodendrocytes is associated with mitochondrial dysfunction and apoptosis-inducing factor translocation. Eur. J. Neurosci. 20(7), 1713-1726 (2004).
81. Carloni S, Buonocore G, Balduini W: Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury. Neurobiol. Dis. DOI: 10.1016/j.nbd.2008.07.022 (2008) (Epub ahed of print).
82. Back SA, Craig A, Kayton RJ et al.: Hypoxia-ischemia preferentially triggers glutamate depletion from oligodendroglia and axons in perinatal cerebral white matter. J. Cereb. Blood Flow Metab. 27(2), 334-347 (2007).
83. Matute C, Alberdi E, Domercq M et al.: Excitotoxic damage to white matter. J. Anat. 210(6), 693-702 (2007).
84. Matute C, Domercq M, Sánchez-Gómez MV: Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 53(2), 212-224 (2006).
85. Felt BT, Lozoff B: Brain iron and behavior of rats are not normalized by treatment of iron deficiency anemia during early development. J. Nutr. 126(3), 693-701 (1996).
86. Gazzolo D, Perrone S, Paffetti P et al.: Non protein bound iron concentrations in amniotic fluid. Clin. Biochem. 38(7), 674-677 (2005).
87. Papanikolau G, Pantopoulos K: Iron metabolism and toxicity. Toxicol. Appl. Pharmacol. 202(2), 199-211 (2005).
88. Lesnefsky EJ: Tissue iron overload and mechanisms of iron-catalyzed oxidative injury. Adv. Exp. Med. Biol. 366, 129-146 (1994).
89. Gaash JA, Lockman PR, Geldenhuys WJ, Allen DD, Van der Schyf CJ: Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells. Neurochem. Res. 32(7), 1196-1208 (2007).
90. Buonocore G, Zani S, Perrone S, Caciotti B, Bracci R: Intraerythrocyte nonprotein-bound iron and plasma malondialdehyde in the hypoxic newborn. Free Radic. Biol. Med. 25(7), 766-770 (1998).
91. Berger HM, Mumby S, Gutteridge JM: Ferrous ions detected in iron-overloaded cord blood plasma from preterm and term babies: implications for oxidative stress. Free Radic. Res. 22(6), 555-559 (1995).
92. Leviton A, Gilles F: Ventriculomegaly, delayed myelination, white matter hypoplasia, and "periventricular" leukomalacia: how are they related? Pediatr. Neurol. 15(2), 127-136 (1996).
93. Savman K, Nilsson UA, Blennow M, Kjellmer I, Whitelaw A: Non-protein-bound iron is elevated in cerebrospinal fluid from preterm infants with posthemorrhagic ventricular dilatation. Pediatr. Res. 49(2), 208-212 (2001).
94. Signorini C, Perrone S, Sgherri C et al.: Plasma esterified F2-isoprostanes and oxidative stress in newborns: role of nonprotein-bound iron. Pediatr. Res. 63(3), 287-291 (2008).
95. Buonocore G, Perrone S, Longini M et al.: Non protein bound iron as early predictive marker of neonatal brain damage. Brain 126(Pt 5), 1224-1230 (2003).
96. Azzopardi D, Edwards AD: Hypothermia. Semin. Fetal Neonatal Med. 12(4), 303-310 (2007).
97. Smith SL, Hall ED: Mild pre- and posttraumatic hypothermia attenuates blood-brain barrier damage following controlled cortical impact injury in the rat. J. Neurotrauma 13(1), 1-9 (1996).
98. Nakashima K, Todd MM: Effects of hypothermia on the rate of excitatory amino acid release after ischemic depolarization. Stroke 27(5), 913-918. (1996).
99. Akisu M, Huseyinov A, Yalaz M, Cetin H, Kultursay N: Selective head cooling with hypothermia suppresses the generation of platelet-activating factor in cerebrospinal fluid of newborn infants with perinatal asphyxia. Prostaglandins Leukot. Essent. Fatty Acids 69(1), 45-50 (2003).
100. Gunn AJ, Thoresen M: Hypothermic neuroprotection. NeuroRx 3(2), 154-169 (2006).
101. Zhu C, Wang X, Xu F et al.: Intraischemic mild hypothermia prevents neuronal cell death and tissue loss after neonatal cerebral hypoxia-ischemia. Eur. J. Neurosci. 23(2), 387-393 (2006).
102. Erecinska M, Thoresen M, Silver IA: Effects of hypothermia on energy metabolism in Mammalian central nervous system. J. Cereb. Blood Flow Metab. 23(5), 513-530 (2003).
103. MacLellan CL, Girgis J, Colbourne F: Delayed onset of prolonged hypothermia improves outcome after intracerebral hemorrhage in rats. J. Cereb. Blood Flow Metab. 24(4), 432-440 (2004).
104. Azzopardi D, Robertson NJ, Cowan FM, Rutherford MA, Rampling M, Edwards AD: Pilot study of treatment with whole body hypothermia for neonatal encephalopathy. Pediatrics 106(4), 684-694 (2000).
105. Xu W, Gu S, Pang L et al.: Peri-operative treatment of most severely head-injured patients. Chin. J. Traumatol. 4(2):67-69 (2001).
106. Horan M, Edwards AD, Firmin RK, Ablett T, Rawson H, Field D: The effect of temperature on the QTc interval in the newborn infant receiving extracorporeal membrane oxygenation (ECMO). Early Hum. Dev. 83(4), 217-223 (2007).
107. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU: Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J. Neuropathol. Exp. Neurol. 60(4), 386-392 (2001).
108. Spandou E, Papadopoulou Z, Soubasi V et al.: Erythropoietin prevents long-term sensorimotor deficits and brain injury following neonatal hypoxia-ischemia in rats. Brain Res. 1045(1-2), 22-30 (2005).
109. van der Kooij MA, Groenendaal F, KavelaarsA, Heijnen CJ, van Bel F: Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res. Rev. 59(1), 22-33 (2008.)
110. Meloni BP, Tilbrook PA, Boulos S, Arthur PG, Knuckey NW: Erythropoietin preconditioning in neuronal cultures: signaling, protection from in vitro ischemia, and proteomic analysis. J. Neurosci. Res. 83(4), 584-593 (2006).
111. Castillo-Meléndez M, Yan E, Walker DW: Expression of erythropoietin and its receptor in the brain of late-gestation fetal sheep, and responses to asphyxia caused by umbilical cord occlusion. Dev. Neurosci. 27(2-4), 220-227 (2005).
112. Juul S, Felderhoff-Mueser U: Epo and other hematopoietic factors. Semin. Fetal Neonatal Med. 12(4), 250-258 (2007).
113. Sola A, Wen TC, Hamrick SE, Ferriero DM: Potential for protection and repair following injury to the developing brain: a role for erythropoietin? Pediatr. Res. 57(5 Pt 2), 110R-117R (2005).
114. Weber A, Dzietko M, Berns M et al.: Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol. Dis. 20(2), 594-600 (2005).
115. McClure MM, Threlkeld SW, Fitch RH: The effects of erythropoietin on auditory processing following neonatal hypoxic-ischemic injury. Brain Res. 1087(1), 190-195 (2006).
116. Tsai PT, Ohab JJ, Kertesz N et al.: A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J. Neurosci. 26(4), 1269-1274 (2006).
117. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M: Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35(7), 1732-1737 (2004).
118. Chong ZZ, Kang JQ, Maiese K: Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J. Cereb. Blood Flow Metab. 22(5), 503-514 (2002).
119. Wei L, Han BH, Li Y, Keogh CL, Holtzman DM, Yu SP: Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whisker-barrel cortex of neonatal rats. J. Pharmacol. Exp. Ther. 317(1), 109-116 (2006).
120. Solaroglu I, Solaroglu A, Kaptanoglu E et al.: Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv. Syst. 19(1), 19-22 (2003).
121. Kumral A, Baskin H, Gokmen N et al.: Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: is it an explanation for the protective role of erythropoietin? Biol. Neonate 85(1), 51-54 (2004).
122. Sun Y, Calvert JW, Zhang JH: Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke 36(8), 1672-1678 (2005).
123. Bierer R, Peceny MC, Hartenberger CH, Ohls RK: Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics. 118(3), E635-E640 (2006).
124. Aher SM, Ohlsson A: Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst. Rev. Issue 3. Art. No.: CD004865. DOI: 10.1002/14651858.CD004865.pub2, (2006).
125. Casadevall N, Eckardt KU, Rossert J: Epoetin-induced autoimmune pure red cell aplasia. J. Am. Soc. Nephrol. 16(Suppl. 1), S67-S69 (2005).
126. 2+-κB. Genes Dev. 18(18), 2195-2224 (2004).
127. 2+-κB pathway in neonatal hypoxic-ischemic brain damage. Stroke 39(9), 2578-2586 (2008).
128. 2+-κB in neuronal plasticity and neurodegenerative disorders. J. Clin. Invest. 107(3), 247-254 (2001).
129. 2+-κB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr. Opin. Cell Biol. 15(6), 732-737 (2003).
130. 2+-κB in the regulation of apoptosis. Oncogene 22(56) 8961-8982 (2003).
131. Chang YC, Huang CC: Perinatal brain injury and regulation of transcription. Curr. Opin. Neurol. 19(2), 141-147 (2006).
132. 2+-ATPase during hypoxia in cerebral cortical neuronal nuclei of newborn piglets. Brain Res. 887(2), 385-390 (2000).
133. Dorrepaal CA, van Bel F, Steendijk P et al.: Influence of inhibition of nitric oxide synthesis on cardiac function in the newborn lamb after hypoxic-ischemic injury. Biol. Neonate 78(2), 98-105 (2000).
134. Fernández AP, Alonso D, Lisazoaín I et al.: Postnatal changes in the nitric oxide system of the rat cerebral cortex after hypoxia during delivery. Brain Res. Dev. Brain Res. 142(2), 177-192 (2003).
135. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 271(5 Pt 1), C1424-C1437 (1996).
136. 2+-κB after neonatal hypoxia-ischemia involves apoptotic mechanisms but is independent of cytokines. Stroke 39(7), 2129-2137 (2008).
137. Peeters-Scholte C, Koster J, Veldhuis W et al.: Neuroprotection by selective nitric oxide synthase inhibition at 24 hours after perinatal hypoxia-ischemia. Stroke 33(9), 2304-2310 (2002).
138. Nijboer CH, Groenendaal F, Kavelaars A, Hagberg HH, van Bel F, Heijnen CJ: Gender-specific neuroprotection by 2-iminobiotin after hypoxia-ischemia in the neonatal rat via a nitric oxide independent pathway. J. Cereb. Blood Flow Metab. 27(2), 282-292 (2007)
139. Marro PJ, Mishra OP, Delivoria-Papadopoulos M: Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets. Brain Res. 1073-1074, 444-450 (2006)
140. Van Bel F, Shadid M, Moison RM et al.: Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics 101(2), 185-193 (1998)
141. Gunes T, Ozturk MA, Koklu E, Kose K, Gunes I: Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns. Pediatr. Neurol. 36(1), 17-24 (2007).
142. Chaudhari T, McGuire W: Allopurinol for preventing mortality and morbidity in newborn infants with suspected hypoxic-ischaemic encephalopathy. Cochrane Database Syst. Rev. 16(2), CD006817 (2008)
143. Marzocchi B, Perrone S, Paffetti P et al.: Nonprotein-bound iron and plasma protein oxidative stress at birth. Pediatr. Res. 58(6), 1295-1269 (2005).
144. Liu Y, Belayev L, Zhao W, Busto R, Belayev A, Ginsberg MD: Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. Eur. J. Pharmacol. 428(2), 193-201 (2001).
145. Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD: The ALIAS pilot yTrial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke - II: neurologic outcome and efficacy analysis. Stroke 37(8), 2107-2114 (2006).
146. Nakka VP, Gusain A, Mehta SL, Raghubir R: Molecular mechanisms of apoptosis in cerebral ischemia: multiple neuroprotective opportunities. Mol. Neurobiol. 37(1), 7-38 (2008)
147. Bazan NG: Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol. Neurobiol. 32(1), 89-103 (2005).
148. Marcheselli VL, Hong S, Lukiw WJ et al.: Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte inflltration and pro-inflammatory gene expression. J. Biol. Chem. 278(44), 43807-43817 (2003).
149. Hurn PD, Koehler RC, Blizzard KK, Traystman RJ: Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. Stroke 26(4), 688-694 (1995).
150. Peeters-Scholte C, Braun K, Koster J et al.: Effects of allopurinol and deferoxamine on reperfusion injury of the brain in newborn piglets after neonatal hypoxia-ischemia. Pediatr. Res. 54(4), 516-522 (2003)
151. Shadid M, Moison R, Steendijk P, Hiltermann L, Berger HM, van Bel F: The effect of antioxidative combination therapy on post hypoxic--ischemic perfusion, metabolism, and electrical activity of the newborn brain. Pediatr. Res. 44(1), 119-124 (1998).
152. Marret S, Doyle LW, Crowther CA, Middleton P: Antenatal magnesium sulphate neuroprotection in the preterm infant. Semin. Fetal Neonatal Med. 12(4), 311-317 2007
153. Hoffman DJ, Marro PJ, McGowan JE, Mishra OP, Delivoria-Papadopoulos M: Protective effect of MgSO4 infusion on NMDA receptor binding characteristics during cerebral cortical hypoxia in the newborn piglet. Brain Res. 644(1), 144-149 (1994).
154. 2+ medium. Magnes. Res. 16(2), 111-119 (2003)
155. Ovbiagele B, Kidwell CS, Starkman S, Saver JL: Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr. Treat. Options Cardiovasc. Med. 6, 441-449 (2003).
156. Macdonald RL, Curry DJ, Aihara Y, Zhang ZD, Jahromi BS, Yassari R: Magnesium and experimental vasospasm. J. Neurosurg. 100(1), 106-110 (2004).
157. Nelson KB, Grether JK: Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics. 95(2), 263-269 (1995).
158. Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P: Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 276(22), 1805-1810 (1996).
159. Harrison V, Fawcus S, Jordaan E: Magnesium supplementation and perinatal hypoxia: outcome of a parallel group randomised trial in pregnancy. BJOG 114(8), 994-1002 (2007).
160. Baraka A, Yazigi A; Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. Anesthesiology 67(5), 806-808 (1987).
161. Lieberman HR, Waldhauser F, Garfield G, Lynch HJ, Wurtman RJ: Effects of melatonin on human mood and performance. Brain Res. Dec 323(2), 201-207 (1984).
162. Vijayalaxmi, Thomas CR Jr, Reiter RJ, Herman TS: Melatonin: from basic research to cancer treatment clinics. J. Clin. Oncol. 20(10), 2575-2601 (2002).
163. Ceraulo L, Ferrugia M, Tesoriere L, Segreto S, Livrea MA, Turco Liveri V: Interactions of melatonin with membrane models: portioning of melatonin in AOT and lecithin reversed micelles. J. Pineal Res. 26(2), 108-112 (1999).
164. Bertuglia S, Marchiafava PL, Colantuoni A: Melatonin prevents ischemic reperfusion injury in hamster cheeck pouch microcirculation. Cardiovasc. Res. 31, 947-952 (1996).
165. Tan DX, Reiter RJ, Manchester LC et al.: Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem. 2(2), 181-197 (2002).
166. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L, Livrea MA: The chemistry of melatonin's interaction with reactive species. J. Pineal Res. 34(1), 1-10 (2003).
167. Reiter RJ, Tan DX, Osuna C, Gitto E: Actions of melatonin in the reduction of oxidative stress. J. Biomed. Sci. 7, 444-458 (2000).
168. Romero MP, Osuna C, Garcia-Perganeda A, Carillo-Vico A, Guerriero JM: The pineal secretory product melatonin reduces hydrogen peroxide-imduced DNA damage in U-937 cells. J. Pineal Res. 26, 227-235 (1999).
169. Welin AK, Svedin P, Lapatto R et al.: Melatonin reduces inflammation and cell death in white matter in the mid-gestation fetal sheep following umbilical cord occlusion. Pediatr. Res. 61(2), 153-158 (2007).
170. Dai J, Ram PT, Yuan L, Spriggs LL, Hill SM: Transcriptional repression of RORα activity in human breast cancer cells by melatonin. Mol. Cell. Endocrinol. 176(1-2), 111-120 (2001).
171. Carrillo-Vico A, García-Mauriño S, Calvo JR, Guerrero JM: Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB J. 17(6), 755-777 (2003).
172. Gitto E, Reiter RJ, Amodio A et al.: Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J. Pineal Res. 36(4), 250-255 (2004).
173. Carloni S, Perrone S, Buonocore G, Longini M, Proietti F, Balduini W: Melatonin protects from the long-term consequences of a neonatal hypoxic-ischemic brain injury in rats. J. Pineal Res. 44(2), 157-164 (2008).